6505--Fluorodeoxyglucose (FDG) Radiopharmaceutical

Solicitation 36C24426Q0900 is a request for quotation issued by the Department of Veterans Affairs Network Contracting Office 4 to secure a Nuclear Regulatory Commission licensed vendor for the supply of Fluorodeoxyglucose (FDG) radiopharmaceuticals. These products serve as tracers for PET/CT scans to detect cancer, evaluate inflammation, and assess organ function at the Philadelphia VA Medical Center. The estimated period of performance runs from October 14, 2026, to October 13, 2031. This is a non-set-aside acquisition for commercial items, with quotes due by September 17, 2026, at 6:00 AM ET. The contractor must adhere to strict packaging and labeling standards, ensuring all shipping containers are marked as radioactive with proper exposure levels and that unit doses include precise preparation and expiration data. Additionally, the vendor must provide bar-labeled inserts compatible with the nuclear medicine information management system, assuming all costs for data migration and training if their system differs from the current Pinestar NMIS. Award will be based on a pairwise comparison of the best overall response, evaluating price, technical capability, socioeconomic considerations, and past performance from the last three years. Payments will be processed via Electronic Funds Transfer through the System for Award Management, with electronic invoicing required via the Tungsten Network.